Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.
Jefferies Upgrades Charles River to Buy, Announces $240 Price Target
Jefferies analyst David Windley upgrades Charles River (NYSE:CRL) from Hold to Buy and announces $240 price target.
